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ORIGINAL ARTICLE
INTRODUCTION
The knowledge of HBeAg and anti-HBe system 
develop from time to time in accordance with the 
molecular biology knowledge advances of hepatitis B 
virus. HBeAg was formerly regarded as an indicator 
of hepatitis B virus replication and was a sign of 
possible chronic liver disease and transmission. On 
the other hand, positive anti-HBe was a marker of 
non-replicative phase, absence of transmission, and 
good prognosis. However, this understanding has 
now changed much; positive HBeAg is indeed still 
an indicator of viral replication and transmission as 
well as a valuable prognostic tool.1 Unlike the old 
understanding, negative HBeAg and positive anti-
HBe does not necessarily indicate that the replication 
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ABSTRACT
Background: Data on HBeAg and anti HBe status in patients with chronic hepatitis B infection are not yet 
available in Indonesia. This study was done to acquire data on HBeAg and anti HBe status in patients with 
hepatitis B chronic infection.
Method: The material of this study was sera, collected from 105 patients with chronic hepatitis B infection 
from June to November 2007, divided into four groups of hepatoma, liver cirrhosis, chronic hepatitis B and 
asymptomatic HBsAg carriers. All sera were examined for HBsAg, HbeAg, anti HBe aside from liver function 
examinations. The sera consisted of 23 sera of patients with hepatoma, 27 with liver cirrhosis, 12 with chronic 
hepatitis B, and 43 with HBsAg asymptomatic carriers.
Results: From 105 samples, only 18.09% samples were in replicative phase, as shown with the positivity of 
HBeAg and the negativity of anti-HBe. Sera with negative HbeAg and positive anti-HBe were mainly found in 
liver cirrhosis (70.73%) and least in chronic hepatitis B (50.00%)
Conclusion: The high frequency of HBeAg negative and anti-HBe positive in this study might indicate the 
possible high frequency of pre core mutation. A study using quantitative HBV DNA should be done to confirm it.
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of hepatitis B virus is low. In patients with pre core 
mutant, it was found that HBeAg is negative and anti 
HBe is positive, but replication still occurs. This is due 
to the inability of the virus to produce HBeAg, although 
it is still replicative. Anti-HBe is positive because at the 
T cells level, HBeAg and HBcAg generate a humoral 
immune response.1,2 Until now there has been no study 
report in Indonesia, which give information about the 
status of HBeAg and anti HBe in chronic hepatitis 
B patients, who are grouped according to clinical 
condition. This data is very important to estimate the 
number of patients with negative HBeAg and positive 
anti HBe due to pre core mutation. 
This study was conducted to determine the status of 
HBeAg and anti HBe in patients with liver disease with 
various clinical forms, ranging from hepatoma, liver 
cirrhosis, chronic hepatitis B and asymptomatic carrier.
METHOD 
The samples of this study are 105 sera taken from 
patients seeking treatment at the Biomedika hospital, 
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showing positive HBsAg from June to November 
2007. Diagnosis was done by history taking, physical 
examination, laboratory examination, ultrasonography, 
and if necessary, histological examination. 
This study used diagnostic criteria that are 
commonly applied. Laboratory examinations for 
HBsAg, HBeAg, and anti-HBe were done using 
artificial imunochromatography made by Acon Lab 
Inc. USA, which according to the Lau et al study has 
a fairly good specificity and sensitivity when compared 
to the ELISA method.3
RESULTS 
Of the 105 sera collected, 19 (18.09%) showed 
positive anti-HBe and negative HBeAg. There were as 
many as 66 (62.86%) patients with negative HBeAg 
and positive anti-HBe, 23 patients with hepatoma aged 
28-59 years old with an average age of 41.08 years 
old. From table 1, it was found that only 3 (13.04%) of 
23 patients with hepatoma were anti-HBe positive and 
HBeAg negative, while 14 (60.87%) patients showed 
negative HBeAg and positive anti HBe. 
positive and anti-HBe negative, while 6 (50.00%) 
patients were HBsAg negative and anti-HBe positive. 
Patients with asymptomatic HBsAg carrier were as 
many as 43 patients, with an age range of 18-55 years 
old and an average of 36.14 years old. From table 4, 
it can be seen that the positive HBeAg and negative 
anti-HBe were found in 9 (20.93%) patients, and 
negative HBsAg and positive anti-HBe in 27 (62.79%) 
patients.
Table 1. HBeAg and anti HBe status in patients with hepatoma 
due to hepatitis B 
HBeAg and anti HBe status Male Female n (%)
HBeAg positive, anti HBe negative 2 1 3 (13.04)
HBeAg negative, anti HBe positive 13 1 14 (60.87)
HBeAg negative, anti HBe negative 4 1 5 (21.73)
HBeAg positive anti HBe positive 1 0 1 (4.35)
Total 20 3 23 (100)
Table 3. HBeAg and anti HBe status in chronic hepatitis B patients 
HBeAg and anti HBe status Male Female n (%)
HBeAg positive; anti HBe negative 2 0 2 (16.67)
HBeAg negative; anti HBe positive 4 2 6 (50.00)
HBeAg negative; anti HBe negative 2 2 4 (33.33)
HBeAg positive; anti HBe positive - - -
Total 8 4 12 (100)
Table 4. HBe Ag and anti-HBe status in asymptomatic HBsAg 
carrier 
HBeAg and anti HBe status Male Female Total
HBeAg positive; anti HBe negative 6 3 9 (20.93%)
HBeAg negative; anti HBe positive 23 4 27 (62.79%)
HBeAg negative; anti HBe negative 4 2 6 (13.95%)
HBeAg positive; anti HBe positive 1 - 1 (2.33%)
Total 34 9 43 (100)
Table 5. HBeAg and anti HBe status in patients with chronic hepatitis B infection
Diagnosis Hepatoma Liver cirrhosis
Chronic 
hepatitis B Asymptomatic carrier Total
HBeAg positive; anti HBe negative 13.04% 18.52% 16.67% 20.93% 18.09%
HBeAg negative; anti HBe positive 60.87% 70.37% 50.00% 62.79% 62.86%
Table 2. HBeAg and anti-HBe status in liver cirrhosis due to 
hepatitis B 
HBeAg and anti HBe status Male Female n (%)
HBeAg positive; anti HBe negative 3 2 5 (18.52)
HBeAg negative; anti HBe positive 11 8 19 (70.37)
HBeAg negative; anti HBe negative 2 1 3 (11.11)
HBeAg positive; anti HBe positive 0 0 0 (0)
Total 16 11 27 (100)
A number of 27 patients with liver cirrhosis 
comprised 11 female patients and 16 male patients with 
an average age of 52.68 years old, with the youngest 
aged 14 years old and the oldest 70 years old. From 
table 2 it is noted that only 5 (18.52%) from 27 patients 
with liver cirrhosis were HBeAg positive and anti-HBe 
negative. On the other hand, liver cirrhosis patients 
with negative HBeAg and positive anti HBe are as 
many as 19 (70.37%) patients. 
There were 12 patients with chronic hepatitis B, 
4 female and 8 male. Patients’ ages range from 24 to 
43 years old, with an average of 36 years old. From 
Table 3, it is recognized that only 2 (16.67%) of 
12 patients with chronic hepatitis B were HBeAg 
DISCUSSION 
There are 4 phases of disease progression in chronic 
hepatitis B, i.e. imunotolerant phase, imunoclearance 
phase, inactive carrier state, and reactivation phases. In 
the imunotolerant phase, there is practically no immune 
response against hepatitis B virus particles so there is 
no cytolysis of infected liver cells and no symptoms.4,5 
In the imunoclearance phase, the levels of 
transaminases are increased, and the body begins to 
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produce an immune response against hepatitis B, which 
will change the positive HBeAg to negative and anti-
HBe to positive. In this phase, clinical symptoms appear 
and transaminases increase at various levels, ranging 
from asymptomatic to severe clinical symptoms that 
can occur repeatedly. Acute exacerbations called flares 
can occur here. When flares happens repeatedly, liver 
cirrhosis will quickly develop.6,7 After imunoclearance 
phase progresses, the patient entered the inactive 
carrier state in which there is practically no clinical 
symptoms, usually normal transaminase, negative 
HBeAg and positive anti HBe.8 However, in some 
patients, although HBeAg negative and anti HBe 
positive, hepatitis B virus replication has not stopped. 
These patients suffer from hepatitis B infection with 
mutant pre core, a virus that has undergone mutation 
that it is not capable of making HBeAg but anti-HBe 
is still formed by the host because at the level of 
T cell immunologic response against the HBcAg and 
HBeAg is the same.1 In patients with wild type HBV, 
HBeAg seroconversion to anti HBe is a good marker 
and the likelihood for cirrhosis and hepatoma to occur 
is small.9,10 In patients with mutant pre core HBV 
infection, due to the persistence of disease activity 
and yet high number of virus particles, cirrhosis and 
hepatoma are more common.
In this study of 105 samples, only 18.09% of 
the replicative phases were recognized from positive 
HBeAg and negative anti-HBe. Ijoma et al reported 
that there were 8.6% of patients with positive HBeAg, 
while from Yap et al a high yield of 43.3% patients 
with HBeAg positive and anti-HBe negative was 
obtained.11,12 In this study, there were 62.86% cases 
showing HBeAg negative and anti-HBe positive. This 
condition was formerly called non-replicative phase, 
but in fact there are 2 possibilities of this situation, 
that are: (1) Wild-type hepatitis B infection which 
have undergone seroconversion called inactive carrier 
state which theoretically has a good prognosis7,9; and 
(2) The patient is included in chronic hepatitis B 
HBeAg negative who has hepatitis B virus infection 
with pre core mutant. Pre core mutant is unable 
to produce HBeAg but can cause a response in 
the form of anti-HBe positive. Both conditions can be 
distinguished by examining the level of HBV DNA. 
In this study, it is noted that the highest cases 
with HBeAg positive and anti-HBe negative were 
in asymptomatic carrier (20.93%) and the lowest in 
hepatoma (13.04%). This is consistent with Rapicetta 
et al who obtained asymptomatic carrier cases as many 
as 87.6%.13 As for the HBeAg negative and anti-HBe 
positive group, most cases were in liver cirrhosis 
(70.37%) and least in chronic hepatitis B (50.00%). 
With the high cases of HBeAg negative and anti HBe 
positive, the incidence of pre core mutation was also 
estimated high. To determine this, further investigation 
is needed regarding the quantitative HBV DNA.
CONCLUSION 
From the high frequency of HBeAg negative and 
anti HBe positive cases in this study, it can be estimated 
that the incidence of pre core mutation was also high. 
Therefore we need further study that uses quantitative 
HBV DNA to verify this.
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